Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TP53BP1
REST API REST API
Homo sapiens
TP53BP1 is differentially expressed in 273 experiments: 118 organism parts: kidney, bone marrow, ... (116 more);, 183 disease states: normal, acute promyelocytic leukemia, ... (181 more);, 90 cell types 193 cell lines 27 compound treatments and 73 other conditions.
Synonyms p202, 53BP1
Orthologs TP53BP1 (Gallus gallus)   TP53BP1 (Bos taurus)   Trp53bp1 (Mus musculus)   TP53BP1 (Danio rerio)   F1M9K1_RAT (Rattus norvegicus)   TP53BP1 (Xenopus laevis)   TP53BP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term chromosome, telomeric region, double-strand break repair via homologous recombination, protein binding, DNA repair, kinetochore, cytoplasm, damaged DNA binding, intracellular, replication fork, condensed chromosome kinetochore, double-strand break repair, positive regulation of transcription from RNA polymerase II promoter, nucleus, chromosome, nucleoplasm, telomeric DNA binding, positive regulation of transcription, DNA-dependent, p53 binding, RNA polymerase II transcription cofactor activity, RNA polymerase II activating transcription factor binding, positive regulation of sequence-specific DNA binding transcription factor activity
InterPro Term BRCT, 53-BP1_Tudor
UniProt Accession B3KVT9, A6NNK5, Q12888, C9JXV0, F8VY86
Search EB-eye ENSG00000067369
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (31 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
U251
2
E-GEOD-20089, E-MTAB-62
SW480
1
2
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
BT474
1
2
E-MTAB-37, E-MEXP-440, E-MTAB-62
MDAMB361
1
E-MTAB-62
cal 27
1
E-MTAB-62
187 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (44 experiments)

Factor Value U/D Experiments
epithelial cell
2
E-GEOD-4483, E-MEXP-2034
embryonic stem cell
2
E-GEOD-26672, E-MEXP-930
CD34+
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18147
M2 macrophage
1
E-GEOD-5099
iPSC derived from hASC using lentiviral reprogramming vector
1
E-GEOD-20033
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-MEXP-2280, E-GEOD-16363, ... (57 experiments)

Factor Value U/D Experiments
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-21912, E-GEOD-8121
lung adenocarcinoma
2
E-GEOD-2514, E-MTAB-62
177 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-15205, E-GEOD-1417, E-TABM-782, ... (21 experiments)

Factor Value U/D Experiments
none
4
5
E-GEOD-5824, E-MEXP-1958, E-MEXP-1601, E-GEOD-1417, E-GEOD-412, ... (9 experiments)
TGF
1
E-GEOD-15205
nickel(II) chloride hexahydrate
1
E-GEOD-6907
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
hydroxyurea
1
E-GEOD-571
vanadium pentoxide
1
E-GEOD-5339
21 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-MTAB-62

Dfs evt
studied in E-GEOD-21653

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-22148, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-MTAB-108, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-GEOD-18005, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-GEOD-20540, E-GEOD-20504, E-GEOD-9764, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-TABM-26, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1460

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.282 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM